Anger Friedrich, Klein Ingo, Löb Stefan, Wiegering Armin, Singh Gurinder, Sperl Dominique, Götze Oliver, Geier Andreas, Lock Johan Friso
Department of General, Visceral and Transplantation Surgery, University Hospital of Würzburg, Würzburg, Germany.
Department of Hepatology, University Hospital of Würzburg, Würzburg, Germany.
Visc Med. 2021 Mar;37(2):94-101. doi: 10.1159/000508172. Epub 2020 Jun 12.
Liver resection is the most effective available therapy for patients with hepatocellular carcinoma (HCC). The accurate selection of patients for surgery requires determination of technical resectability and the risk of recurrence, as well as assessment of liver function and functional reserve to avoid postoperative liver failure. Previous studies have underlined the effectiveness and reliability of the LiMAx® test to evaluate liver function preoperatively. Nevertheless, data concerning HCC evaluation are lacking.
From 2014 to 2019, 92 patients with HCC underwent additional assessment of liver function using the LiMAx test prior to decision for or against liver resection. Preoperative LiMAx results were compared between cirrhotic and noncirrhotic liver. The clinical decision for surgery was evaluated applying the various liver function parameters available.
Forty-six patients underwent liver resection. The LiMAx results were higher in resected patients (388 vs. 322 µg/kg/h; = 0.004). LiMAx values were an independent risk factor for the presence of liver cirrhosis in multivariate analysis. In 17 patients, surgical treatment was cancelled due to major impairment of liver function. Only 4 out of 46 resected patients presented with post-hepatectomy liver failure (PHLF) grade ≥B. Histologic assessment revealed liver cirrhosis in 10 resected patients without PHLF.
Preoperative determination of liver function by the LiMAx test enables effective and safe patient selection for HCC resection in both cirrhotic and noncirrhotic liver.
肝切除术是肝细胞癌(HCC)患者最有效的现有治疗方法。准确选择手术患者需要确定技术可切除性和复发风险,以及评估肝功能和功能储备以避免术后肝衰竭。先前的研究强调了LiMAx®测试术前评估肝功能的有效性和可靠性。然而,关于HCC评估的数据尚缺乏。
2014年至2019年,92例HCC患者在决定是否进行肝切除术前使用LiMAx测试进行了肝功能的额外评估。比较了肝硬化和非肝硬化肝脏术前LiMAx的结果。应用现有的各种肝功能参数评估手术的临床决策。
46例患者接受了肝切除术。接受肝切除术患者的LiMAx结果更高(388 vs. 322 μg/kg/h;P = 0.004)。在多变量分析中,LiMAx值是肝硬化存在的独立危险因素。17例患者因肝功能严重受损取消了手术治疗。46例接受肝切除术的患者中只有4例出现了≥B级肝切除术后肝衰竭(PHLF)。组织学评估显示,10例接受肝切除术且未发生PHLF的患者存在肝硬化。
通过LiMAx测试术前确定肝功能能够在肝硬化和非肝硬化肝脏中有效且安全地选择HCC切除患者。